85. The Perception Of Teratogenic Risk By Women With Nausea And Vomiting Of Pregnanc
Paolo Mazzotta, MSc, laura A. Magee, MD, FRCPC, MSc, Caroline Maltepe, MA, ArielahLifshitz, Yvette Navioz, Gideon Koren, MD, FACCT, FRCPC
http://www.nvp-volumes.org/p2_2.htm |
The perception of teratogenic risk by women with nausea and vomiting of pregnancy* Paolo Mazzotta, MSc, Laura A. Magee, MD, FRCPC, MSc, Caroline Maltepe, MA, Arielah Lifshitz, Yvette Navioz, Gideon Koren, MD, FACCT, FRCPC
The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and Research Institute, The Hospital for Sick Children, Toronto, Department of Pediatrics, Pharmacology, Pharmacy and Medicine, the University of Toronto, Toronto, Ontario, Canada
Supported by a grant from Duchesnay Inc., Laval, Quebec * Published in Reproductive Toxicology,1999;13:313-9. Introduction Since the thalidomide disaster of the late 1950s and early 1960s, pharmacological interventions used to treat women suffering from nausea and vomiting of pregnancy (NVP) have been viewed with great trepidation. As a result, "morning sickness" (as it is most commonly known) has been commonly treated with either dietary or lifestyle changes which have been empirically derived. Effective and safe pharmacological therapies have often been avoided; in fact, Bendectin was actually withdrawn from the world market because of unsubstantiated claims of teratogenicity and the unwillingness of the manufacturer to pay litigation costs. The Motherisk Program, at the Hospital for Sick Children in Toronto, receives numerous inquiries each month regarding the safety and/or effectiveness of antiemetic medications for NVP. Unlike in the United States, Diclectin (doxylamine/pyridoxine), a generic form of Bendectin, is indicated for the treatment of NVP and is available to patients in Canada suffering from this disorder of pregnancy. | |
|
